BioNTech SE American Depositary Share (BNTX)
BNTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/0001776985-26-000017-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | BNTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Germany |
| IPO year | 2019 |
| SEC CIK | 0001776985 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Germany |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | -$1.3B |
| Operating income | -$1.6B |
| Net margin | -39.6% |
| Operating margin | -49.0% |
| Revenue growth | +4.3% |
| Cash | $8.5B |
| Total assets | $24.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.8× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-10 |
| Cash and burn | 7.7B EUR cash; operating cash flow 114.0M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 252,884,261 (2026-03-31); 239,970,804 a year earlier; 240,993,998 three years earlier. the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures. | Cover page 2026-03-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EY GmbH & Co. KG Wirtschaftspruefungsgesellschaft, Cologne, Germany | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $69.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 2.9B EUR | -1.1B EUR | 456.0M EUR | 7.7B EUR | No debt tags | 2.9B EUR | 20-F 2026-03-10 |
| FY 2024 2024-12-31 | 2.8B EUR | -665.3M EUR | 207.7M EUR | 9.8B EUR | No debt tags | 2.8B EUR | 20-F 2026-03-10 |
| FY 2023 2023-12-31 | 3.8B EUR | 930.3M EUR | 5.4B EUR | 11.7B EUR | No debt tags | 3.8B EUR | 20-F 2026-03-10 |
| FY 2022 2022-12-31 | 17.3B EUR | 9.4B EUR | 13.6B EUR | 13.9B EUR | No debt tags | 17.3B EUR | 20-F 2025-03-10 |
| FY 2021 2021-12-31 | 19.0B EUR | 10.3B EUR | 889.7M EUR | 1.7B EUR | 301.5M EUR | 19.0B EUR | 20-F 2024-03-20 |
| FY 2020 2020-12-31 | 482.3M EUR | 15.2M EUR | -13.5M EUR | 1.2B EUR | 240.1M EUR | 482.3M EUR | 20-F 2023-03-27 |
| FY 2019 2019-12-31 | 108.6M EUR | -179.1M EUR | -198.5M EUR | 519.1M EUR | 74.2M EUR | 108.6M EUR | 20-F/A 2022-10-26 |
| FY 2018 2018-12-31 | 127.6M EUR | -48.0M EUR | -58.9M EUR | 411.5M EUR | No debt tags | 127.6M EUR | 20-F 2021-03-30 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-11-14 |
| Latest annual report | 20-F | 2026-03-10 |
| Latest quarterly / interim | 6-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 590 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.2% |
| 1 month | -3.8% |
| 3 months | -7.1% |
| Year to date | -10.1% |
| 1 year | -17.6% |
| From 52-week high | -28.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
| RVMD | Revolution Medicines Inc. | $166.87 | -3.15% | $36.1B |
| BIIB | Biogen Inc. | $251.65 | -0.69% | $37.2B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier